Objective:To test IGF signal pathway IGF1 key protein, IGF1R and AKT in ovarian cancer with cispl-atin drug resistance. Methods: Using the ATP - TCA method to test susceptibility in 40 cases with ovarian cancer, including 16 cases of drug resistance of cisplatin, 24 cases of cisplatin sensitive. ELISA test serum IGF1, IGFR and AKT expression. Micro particle capture immune luminous technology ( MEIA) was used to test 40 cases epithelial o-varian cancer patients before treatment, before the operation after the surgery and 7 to 14 days,for serum CA125 concentration. Results: IGF1, IGF1R and AKT cisplatin in ovarian cancer drug resistance group was significantly higher than the expression of sensitive group (P =0. 0001 ) , cisplatin resistance CA125 half - life and sensitive group patients was different with patients who have statistical significance. Conclusion: IGF signal pathway IGF1 key protein, IGF1R and AKT cisplatin might be involved in ovarian cancer drug resistance, CA125 half-life, IGF1R and AKT joint IGF1 test can predict early ovarian cancer chemotherapy drug resistance.%目的:检测IGF信号通路关键蛋白IGF1、IGF1R及AKT在顺铂耐药卵巢癌患者血清中的表达,检测血清CA125的动态变化,探讨与卵巢癌耐药患者预后的关系.方法:利用ATP-TCA法对40例卵巢癌标本进行药敏试验,其中16例对顺铂耐药,24例对顺铂敏感,ELISA法分别检测顺铂耐药和敏感组患者血清中IGF1、IGF1R及AKT的表达.采用微粒子捕捉免疫发光技术(MEIA)测定40例卵巢上皮癌患者治疗前、手术前及手术后7-14天、每疗程化疗后血清中CA125浓度,计算CA125半衰期,探讨与预后的关系.结果:IGF1、IGF1R及AKT在卵巢癌顺铂耐药组的表达显著高于敏感组(P值均为0.0001),顺铂耐药患者CA125半衰期与敏感组患者相比有统计学意义.结论:IGF信号通路关键蛋白IGF1、IGF1R及AKT可能参与卵巢癌顺铂耐药,CA125半衰期联合IGF1、IGF1R及AKT检测可早期预测卵巢癌化疗耐药.
展开▼
